Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Poor clinical trial results have pushed two companies to each cut about 80% of their staff, including top executives, as they determine how to move ahead. In December, Ophthotech reported that its anti-PDGF therapy Fovista failed to show any benefit in two late-stage macular degeneration trials. At the time, the company had about 154 employees. Separately, Nivalis Therapeutics is restructuring and will retain just five of its 30 employees after a disappointing Phase II trial of its cystic fibrosis drug cavosonstat.
This article has been sent to the following recipient: